Elicio Therapeutics (ELTX) Competitors

$9.95 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$9.98 +0.03 (+0.25%)

As of 05/22/2026 05:28 PM Eastern

ELTX vs. ABUS, ETON, KURA, ABSI, and DRUG

Should you buy Elicio Therapeutics stock or one of its competitors? MarketBeat compares Elicio Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Elicio Therapeutics include Arbutus Biopharma (ABUS), Eton Pharmaceuticals (ETON), Kura Oncology (KURA), Absci (ABSI), and Bright Minds Biosciences (DRUG). These companies are all part of the "med - biomed/gene" industry.

How does Elicio Therapeutics compare to Arbutus Biopharma?

Elicio Therapeutics (NASDAQ:ELTX) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

Elicio Therapeutics has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market.

Arbutus Biopharma has higher revenue and earnings than Elicio Therapeutics. Elicio Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.40	N/A
Arbutus Biopharma	$14.08M	61.03	-$33.50M	$0.83	5.24

Arbutus Biopharma has a net margin of 83.95% compared to Elicio Therapeutics' net margin of 0.00%. Arbutus Biopharma's return on equity of 129.32% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-2,748.16%	-151.12%
Arbutus Biopharma	83.95%	129.32%	112.24%

In the previous week, Elicio Therapeutics' average media sentiment score of 0.00 equaled Arbutus Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Elicio Therapeutics	Neutral
Arbutus Biopharma	Neutral

35.0% of Elicio Therapeutics shares are owned by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are owned by institutional investors. 50.9% of Elicio Therapeutics shares are owned by insiders. Comparatively, 19.9% of Arbutus Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Elicio Therapeutics currently has a consensus target price of $18.00, suggesting a potential upside of 80.90%. Arbutus Biopharma has a consensus target price of $5.00, suggesting a potential upside of 14.94%. Given Elicio Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Elicio Therapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Arbutus Biopharma beats Elicio Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Elicio Therapeutics compare to Eton Pharmaceuticals?

Elicio Therapeutics (NASDAQ:ELTX) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.

35.0% of Elicio Therapeutics shares are owned by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are owned by institutional investors. 50.9% of Elicio Therapeutics shares are owned by insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Elicio Therapeutics has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market.

Elicio Therapeutics presently has a consensus target price of $18.00, suggesting a potential upside of 80.90%. Eton Pharmaceuticals has a consensus target price of $41.00, suggesting a potential upside of 25.81%. Given Elicio Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Elicio Therapeutics is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Elicio Therapeutics has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -1.70%. Eton Pharmaceuticals' return on equity of -5.68% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-2,748.16%	-151.12%
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%

In the previous week, Eton Pharmaceuticals had 3 more articles in the media than Elicio Therapeutics. MarketBeat recorded 3 mentions for Eton Pharmaceuticals and 0 mentions for Elicio Therapeutics. Eton Pharmaceuticals' average media sentiment score of 0.25 beat Elicio Therapeutics' score of 0.00 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Elicio Therapeutics	Neutral
Eton Pharmaceuticals	Neutral

Eton Pharmaceuticals has higher revenue and earnings than Elicio Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.40	N/A
Eton Pharmaceuticals	$79.95M	11.16	-$4.60M	-$0.07	N/A

Summary

Elicio Therapeutics and Eton Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Elicio Therapeutics compare to Kura Oncology?

Elicio Therapeutics (NASDAQ:ELTX) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

Elicio Therapeutics has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market.

Elicio Therapeutics has higher earnings, but lower revenue than Kura Oncology. Elicio Therapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.40	N/A
Kura Oncology	$67.48M	14.80	-$278.67M	-$3.35	N/A

In the previous week, Kura Oncology had 2 more articles in the media than Elicio Therapeutics. MarketBeat recorded 2 mentions for Kura Oncology and 0 mentions for Elicio Therapeutics. Kura Oncology's average media sentiment score of 0.30 beat Elicio Therapeutics' score of 0.00 indicating that Kura Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Elicio Therapeutics	Neutral
Kura Oncology	Neutral

Elicio Therapeutics has a net margin of 0.00% compared to Kura Oncology's net margin of -411.19%. Kura Oncology's return on equity of -141.95% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-2,748.16%	-151.12%
Kura Oncology	-411.19%	-141.95%	-43.28%

Elicio Therapeutics currently has a consensus price target of $18.00, suggesting a potential upside of 80.90%. Kura Oncology has a consensus price target of $26.38, suggesting a potential upside of 134.44%. Given Kura Oncology's higher possible upside, analysts plainly believe Kura Oncology is more favorable than Elicio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

35.0% of Elicio Therapeutics shares are owned by institutional investors. 50.9% of Elicio Therapeutics shares are owned by company insiders. Comparatively, 7.6% of Kura Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Elicio Therapeutics and Kura Oncology tied by winning 8 of the 16 factors compared between the two stocks.

How does Elicio Therapeutics compare to Absci?

Absci (NASDAQ:ABSI) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

Absci currently has a consensus price target of $7.53, indicating a potential upside of 47.55%. Elicio Therapeutics has a consensus price target of $18.00, indicating a potential upside of 80.90%. Given Elicio Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Elicio Therapeutics is more favorable than Absci.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Absci	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Elicio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Absci had 2 more articles in the media than Elicio Therapeutics. MarketBeat recorded 2 mentions for Absci and 0 mentions for Elicio Therapeutics. Absci's average media sentiment score of 0.44 beat Elicio Therapeutics' score of 0.00 indicating that Absci is being referred to more favorably in the media.

Company	Overall Sentiment
Absci	Neutral
Elicio Therapeutics	Neutral

Elicio Therapeutics has a net margin of 0.00% compared to Absci's net margin of -6,450.76%. Absci's return on equity of -66.32% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Absci	-6,450.76%	-66.32%	-57.01%
Elicio Therapeutics	N/A	-2,748.16%	-151.12%

52.1% of Absci shares are held by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are held by institutional investors. 10.5% of Absci shares are held by company insiders. Comparatively, 50.9% of Elicio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Absci has a beta of 2.36, meaning that its share price is 136% more volatile than the broader market. Comparatively, Elicio Therapeutics has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

Elicio Therapeutics has lower revenue, but higher earnings than Absci. Absci is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Absci	$2.80M	283.96	-$115.18M	-$0.83	N/A
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.40	N/A

Summary

Absci beats Elicio Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Elicio Therapeutics compare to Bright Minds Biosciences?

Bright Minds Biosciences (NASDAQ:DRUG) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

40.5% of Bright Minds Biosciences shares are owned by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by company insiders. Comparatively, 50.9% of Elicio Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Bright Minds Biosciences had 2 more articles in the media than Elicio Therapeutics. MarketBeat recorded 2 mentions for Bright Minds Biosciences and 0 mentions for Elicio Therapeutics. Bright Minds Biosciences' average media sentiment score of 2.04 beat Elicio Therapeutics' score of 0.00 indicating that Bright Minds Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Bright Minds Biosciences	Very Positive
Elicio Therapeutics	Neutral

Bright Minds Biosciences' return on equity of -20.58% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-20.58%	-20.25%
Elicio Therapeutics	N/A	-2,748.16%	-151.12%

Bright Minds Biosciences presently has a consensus target price of $143.83, indicating a potential upside of 72.26%. Elicio Therapeutics has a consensus target price of $18.00, indicating a potential upside of 80.90%. Given Elicio Therapeutics' higher possible upside, analysts clearly believe Elicio Therapeutics is more favorable than Bright Minds Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Elicio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Bright Minds Biosciences has a beta of -5.35, indicating that its share price is 635% less volatile than the broader market. Comparatively, Elicio Therapeutics has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.40	N/A

Summary

Bright Minds Biosciences beats Elicio Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Elicio Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELTX vs. The Competition

Export

Metric	Elicio Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$189.91M	$3.37B	$6.45B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-4.15	18.74	21.22	25.65
Price / Sales	N/A	323.98	553.92	86.28
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	-124.38	7.09	10.37	7.14
Net Income	-$39.57M	$24.45M	$3.57B	$335.98M
7 Day Performance	3.97%	5.45%	6.01%	3.56%
1 Month Performance	-14.88%	2.43%	3.52%	2.54%
1 Year Performance	75.80%	62.98%	34.13%	35.05%

Elicio Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELTX Elicio Therapeutics	1.6752 of 5 stars	$9.95 flat	$18.00 +80.9%	+75.8%	$189.91M	N/A	N/A	N/A
ABUS Arbutus Biopharma	1.6558 of 5 stars	$4.35 +0.9%	$5.00 +14.9%	+35.1%	$848.81M	$14.08M	5.24	90	Gap Up
ETON Eton Pharmaceuticals	4.0155 of 5 stars	$29.96 -2.8%	$39.33 +31.3%	+64.5%	$843.23M	$79.95M	N/A	20	Gap Up
KURA Kura Oncology	2.442 of 5 stars	$9.74 +2.7%	$26.38 +170.8%	+99.5%	$841.58M	$67.48M	N/A	130
ABSI Absci	3.6358 of 5 stars	$5.54 +4.5%	$7.53 +35.8%	+91.7%	$826.30M	$2.80M	N/A	210

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELTX) was last updated on 5/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Elicio Therapeutics (ELTX) Competitors

ELTX vs. ABUS, ETON, KURA, ABSI, and DRUG

How does Elicio Therapeutics compare to Arbutus Biopharma?

Summary

How does Elicio Therapeutics compare to Eton Pharmaceuticals?

Summary

How does Elicio Therapeutics compare to Kura Oncology?

Summary

How does Elicio Therapeutics compare to Absci?

Summary

How does Elicio Therapeutics compare to Bright Minds Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELTX vs. The Competition

Elicio Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Elicio Therapeutics (ELTX) Competitors

ELTX vs. ABUS, ETON, KURA, ABSI, and DRUG

How does Elicio Therapeutics compare to Arbutus Biopharma?

Which has more volatility and risk, ELTX or ABUS?

Which has preferable earnings & valuation, ELTX or ABUS?

Is ELTX or ABUS more profitable?

Does the media refer more to ELTX or ABUS?

Do insiders and institutionals hold more shares of ELTX or ABUS?

Do analysts rate ELTX or ABUS?

Summary

How does Elicio Therapeutics compare to Eton Pharmaceuticals?

Do institutionals & insiders have more ownership in ELTX or ETON?

Which has more volatility & risk, ELTX or ETON?

Do analysts prefer ELTX or ETON?

Is ELTX or ETON more profitable?

Does the media refer more to ELTX or ETON?

Which has higher valuation & earnings, ELTX or ETON?

Summary

How does Elicio Therapeutics compare to Kura Oncology?

Which has more risk and volatility, ELTX or KURA?

Which has preferable earnings and valuation, ELTX or KURA?

Does the media refer more to ELTX or KURA?

Is ELTX or KURA more profitable?

Do analysts prefer ELTX or KURA?

Do insiders & institutionals hold more shares of ELTX or KURA?

Summary

How does Elicio Therapeutics compare to Absci?

Do analysts prefer ABSI or ELTX?

Does the media favor ABSI or ELTX?

Is ABSI or ELTX more profitable?

Do institutionals and insiders hold more shares of ABSI or ELTX?

Which has more volatility and risk, ABSI or ELTX?

Which has better earnings & valuation, ABSI or ELTX?

Summary

How does Elicio Therapeutics compare to Bright Minds Biosciences?

Do insiders and institutionals believe in DRUG or ELTX?

Does the media prefer DRUG or ELTX?

Is DRUG or ELTX more profitable?

Do analysts recommend DRUG or ELTX?

Which has more risk and volatility, DRUG or ELTX?

Which has better earnings & valuation, DRUG or ELTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELTX vs. The Competition

Elicio Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools